PEG-rhG-CSF

ApprovedSmall molecule

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

PEG-rhG-CSF is one of 323 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

322

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Aplastic AnemiaActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

Hemophagocytic SyndromeActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Cervical CancerActive, not recruiting

NeutropeniaApproved

Active, not recruiting

Nasopharyngeal CarcinomaPhase 1

Active, not recruiting

Aplastic AnemiaPreclinical

Active, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Hemophagocytic SyndromePreclinical

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Ovarian CancerApproved

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

PEG-rhG-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Approved

4 2

Zolymbus

AbbVie

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Chirocaine

PPurdue Pharma LP

Preclinical

1 5

Acupan

YYonsei University

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Avastin

Roche

Preclinical

4 8

Vfend

PPrism Pharmaceuticals

Paracetamol

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Lymphoma

NCT06520163

Q4 2027

Phase 3Recruiting

Esophageal Cancer

NCT03731442

Clinical

Trials by Indication[1]

Lymphoma6 trials

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Unknown status·OOu Bai, MD/PHD·N/A·NCT05834751·144 enrolled

PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Unknown status·PPeking University·Phase 4·NCT02905942·96 enrolled

PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

Completed·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 4·NCT02805218·410 enrolled

Show 3 more trials

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Unknown status·SSun Yat-sen University·N/A·NCT05156554·80 enrolled

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Recruiting·—·Phase 3·NCT06520163·99 enrolled

Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients

Unknown status·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·N/A·NCT03870412·485 enrolled

Neutropenia5 trials

The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

Unknown status·Wwang shusen·Phase 3·NCT02761460·338 enrolled

Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Unknown status·RRuijin Hospital·Phase 4·NCT04083079·250 enrolled

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Unknown status·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·N/A·NCT04497688·104 enrolled

Show 2 more trials

The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy

Unknown status·PPeking University·Phase 4·NCT02905916·217 enrolled

Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

Unknown status·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.··NCT03846414·1,500 enrolled

Breast Cancer4 trials

Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer

Completed·PPeking University·Phase 4·NCT04009941·104 enrolled

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia

Completed·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 4·NCT02805205·484 enrolled

The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy

Completed·PPeking University·Phase 4·NCT02944604·240 enrolled

Show 1 more trial

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

Completed·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 4·NCT02805153·215 enrolled

Cervical Cancer2 trials

To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer

Unknown status·—·Phase 4·NCT03206684·20 enrolled

Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

Completed·—·Phase 2·NCT04542356·60 enrolled

Effectiveness1 trial

Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis

Unknown status·—··NCT03701841·1,000 enrolled

16 more indications

Adolescent1 trial

The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents

Completed·CChinese Academy of Medical Sciences·Phase 4·NCT02953730·9 enrolled

Pancreatic Cancer1 trial

Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Unknown status·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·N/A·NCT04239001·20 enrolled

Ovarian Cancer1 trial

Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer

Terminated·SShandong University·Phase 4·NCT03858166·68 enrolled

Hematopoietic Stem Cell Transplant1 trial

The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization

Unknown status·ZZhongnan Hospital·Phase 1·NCT05970185·40 enrolled

Hematopoietic Stem Cell Mobilization1 trial

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Unknown status·—·N/A·NCT05510089·62 enrolled

Recruiting·—·N/A·NCT05536154·68 enrolled

Nasopharyngeal Carcinoma1 trial

G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 1·NCT05222009·25 enrolled

Stem Cells1 trial

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Unknown status·—·Phase 4·NCT06026995·174 enrolled

Aplastic Anemia1 trial

A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT05531279·45 enrolled

Malignant Solid Tumors1 trial

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

Completed·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 4·NCT02805166·420 enrolled

Esophageal Cancer1 trial

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Recruiting·CChinese Academy of Medical Sciences·Phase 3·NCT03731442·300 enrolled

Stem Cell1 trial

A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF

Unknown status·NNing Huang·Phase 4·NCT05409547·80 enrolled

Adult Subject1 trial

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects

Completed·AAdello Biologics, LLC·Phase 1·NCT03206229·120 enrolled

Efficacy and Safety1 trial

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Completed·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 2/3·NCT04554056·586 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for PEG-rhG-CSF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-rhG-CSF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-rhG-CSF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

PEG-rhG-CSF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Trials by Indication[1]

Lymphoma6 trials

Neutropenia5 trials

Breast Cancer4 trials

Cervical Cancer2 trials

Effectiveness1 trial

Adolescent1 trial

Pancreatic Cancer1 trial

Ovarian Cancer1 trial

Hematopoietic Stem Cell Transplant1 trial

Hematopoietic Stem Cell Mobilization1 trial

Small Cell Lung Cancer1 trial

Hemophagocytic Syndrome1 trial

Hematological Malignancies1 trial

Nasopharyngeal Carcinoma1 trial

Stem Cells1 trial

Aplastic Anemia1 trial

Malignant Solid Tumors1 trial

Esophageal Cancer1 trial

Stem Cell1 trial

Adult Subject1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News